Why Rigel Pharmaceuticals Stock Is Rocketing Higher Today

Rigel Pharmaceuticals Inc RIGL shares are on the move Wednesday after the company reported fourth-quarter results well above analyst expectations.

What Happened: Rigel reported fourth-quarter revenues of $51.3 million, which beat consensus estimates of $27.97 million, according to Benzinga Pro. The company reported quarterly earnings of 1 cent per share, which beat estimates for a loss of 11 cents per share.

Total costs and expenses came in at $49.2 million for the fourth quarter, up from $41.8 million year-over-year due to an increase in personnel-related costs and commercial expenses, as well as higher research and development costs.

"We are focused on continuing the successful launch of REZLIDHIA in R/R AML, driving sales growth for TAVALISSE in ITP, and advancing our development programs. In 2023, we look forward to further expanding our hematology-oncology portfolio and clinical pipeline," said Raul Rodriguez, president and CEO of Rigel Pharmaceuticals. 

Following the print, HC Wainwright & Co analyst Joseph Pantginis reiterated Rigel with a Buy rating and maintained a $15 price target, which is significantly higher than where the stock is currently trading. 

Rigel develops small-molecule drugs for autoimmune, cancer-related, and viral diseases.

See Also: Nasdaq, S&P 500 Futures Point To Cautious Optimism As Traders Look Ahead To More Of Powell, ADP Private Payrolls Report

RIGL Price Action: Rigel has a 52-week high of $3.51 and a 52-week low of 64 cents.

The stock was up 26.5% at $1.86 at the time of writing, according to Benzinga Pro.

Photo: Konstantin Kolosov from Pixabay.

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!